Danlin is a results-oriented leader with more than 14 years of experience in biotherapeutics discovery. With a strong foundation in biophysics and chemical engineering, she is passionate about driving discovery and early CMC development in the most expedited manner. Danlin joined Third Arc Bio in April 2022 as the company’s second employee and has been pivotal in rapidly building a strong oncology and immunology portfolio that contributed to a successful $165M Series A funding round in 2024. In her current role as VP of discovery and CMC strategies and operations, Danlin provides scientific and operational leadership to advance the company's biologic pipeline.

Previously, she held roles of increasing responsibilities at Johnson & Johnson (J&J) and Boehringer Ingelheim, where she played a critical role in advancing numerous projects to IND-enabling studies, many of which are now in clinical development. Danlin has published more than a dozen peer-reviewed articles and is a co-inventor of more than 20 patent applications, spanning biologic molecules and platform technologies.

She earned her PhD in biophysics and biochemistry from the University of New Hampshire and holds advanced degrees in biotechnology and chemical engineering.